Yipin Bio Completes Tens of Millions of RMB Series A Funding to Accelerate Integrated CRTDMO Platform for Medical Devices
It is reported that Guiyang Yipin Biotechnology Co., Ltd. (hereinafter referred to as “Yipin Biotech”), a subsidiary of Yipin (Guiyang) Quality Technology Co., Ltd. (hereinafter referred to as “Yipin Tech”), has officially announced the completion of its Series A financing round, amounting to tens of millions of yuan. This round was led by Guiyang Venture Capital Co., Ltd., with participation from GuiYang Health Investment Group and Guiyang Baiyun Industrial Co., Ltd.
"This round of financing will primarily be used to accelerate the construction of a high-level passive medical device CDMO platform at the Medical Device Industrial Park in Baiyun District, Guiyang City, focusing on providing related services for product categories such as medical aesthetics, gels, catheters, and IVD reagents."
Leveraging Yipin Technology’s years of strategic layout in comprehensive preclinical research and full-discipline testing and inspection CRO services, Yipin Biology has established end-to-end capabilities covering collaborative R&D, supply chain management, contract manufacturing, quality systems, testing and inspection, animal studies, clinical trials, and product registration. It is dedicated to providing one-stop CRTDMO solutions for passive medical consumables, medical aesthetics, and IVD reagents.
As a leading medical device CRO company in China, Yipin Technology will enhance its post-registration production and service capabilities for medical device products through the expansion of Yipin Biotechnology’s CDMO business. Previously, Guiyang Venture Capital Co., Ltd. and Baiyun Industrial Investment (a subsidiary of Baiyun Industrial) had participated in multiple financing rounds of Yipin Technology. The recent investment by three Guizhou state-owned enterprises in Yipin Biotechnology’s CDMO platform demonstrates their full recognition and support for Yipin’s platform-based development strategy and its efforts to build an integrated medical device CRTDMO ecosystem.
Guiyang Venture Capital, the investor in this round, stated: As a scarce integrated CRTDMO service provider in the fields of IVD reagents and medical dressings, Yipin Biotechnology possesses full-process service capabilities covering R&D, testing and inspection, and production. Currently, the market size for IVD reagents and medical dressings is growing rapidly. Leveraging Yipin Technology’s accumulated experience and strong customer reputation, along with support from local governments, Yipin Biotechnology is poised for rapid growth.
Guiyang Health Investment Group, the investor in this round, stated: As an emerging business unit of the Yipin Group, Yipin Biotechnology has attracted significant attention for its innovative capabilities and market prospects. GuiYang Health Investment Group looks forward to further promoting the robust development of Yipin Biotechnology in the field of medical devices through this investment, thereby making a significant contribution to enhancing overall healthcare standards and safeguarding the health and well-being of the general public.
Yipin Group is a medical device technology service platform with government investment backing. The company focuses on the rapidly developing medical device and biopharmaceutical industries, providing domestic and international manufacturers and research institutions with one-stop CRO services covering preclinical research, testing and inspection, large animal studies, clinical trials, and regulatory registration.
Yipin Laboratory is one of the few asset-heavy laboratories in China. It has built and operates nearly 40,000 square meters of medical device laboratory space across the country, having served over 5,000 clients to date. The laboratory has obtained accreditations including CNAS and CMA in China, as well as A2LA and IAS in the United States, enabling it to provide rigorous, scientific data, solutions, and reports for the Chinese, U.S., and European markets. Its service capabilities cover the full spectrum of medical devices, including electronic medical devices, orthopedics, implants and interventional products, biomaterials, sterile consumables, IVD, and software. Yipin offers comprehensive testing services such as electrical safety testing, performance testing, EMC (electromagnetic compatibility), animal studies, chemical characterization, microbiological testing, biocompatibility, cleaning/disinfection/sterilization validation, packaging aging, and physicochemical property testing, thereby meeting diverse R&D and testing needs throughout the process from product development to clinical registration.
Yipin Biotechnology is a company under the Yipin Group that specializes in CDMO services for medical devices. Leveraging high-quality resources and policy support from the Guizhou Provincial, Guiyang Municipal, and Baiyun District governments, Yipin Biotechnology works in close collaboration with government industrial parks. It aims to address issues of confidentiality, timeliness, and impartiality in the contracted R&D and manufacturing of medical devices, helping enterprises achieve product registration and establish production capacity with low cost, high quality, and high efficiency. This facilitates the regional transfer of medical device production capacity, efficient integration of upstream and downstream services and supply chains, and the implementation and development of scientific research translation and medical-engineering translation in Guiyang.